UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Activation and regulation of purinergic P2X receptor channels

Pharmacological reviews, 2011-09, Vol.63 (3), p.641-683

2011

Volltextzugriff (PDF)

Action of MK‐7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation

British journal of pharmacology, 2019-07, Vol.176 (13), p.2279-2291

2019

Volltextzugriff (PDF)

X-ray structures define human P2X(3) receptor gating cycle and antagonist action

Nature (London), 2016-10, Vol.538 (7623), p.66

2016

Volltextzugriff (PDF)

Purinergic P2X receptors: Structural models and analysis of ligand-target interaction

European journal of medicinal chemistry, 2015-01, Vol.89, p.561-580

2015

Volltextzugriff (PDF)

The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease

Pharmacological reviews, 2014-07, Vol.66 (3), p.638-675

2014

Volltextzugriff (PDF)

P2X7 receptor antagonism: Implications in diabetic retinopathy

Biochemical pharmacology, 2017-08, Vol.138, p.130-139

2017

Volltextzugriff (PDF)

P2X7 receptor in multifaceted cellular signalling and its relevance as a potential therapeutic target in different diseases

European journal of pharmacology, 2021-09, Vol.906, p.174235-174235, Article 174235

2021

Volltextzugriff (PDF)

Discovery of Triazolopyrimidine Derivatives as Selective P2X3 Receptor Antagonists Binding to an Unprecedented Allosteric Site as Evidenced by Cryo-Electron Microscopy

Journal of medicinal chemistry, 2024-08, Vol.67 (16), p.14443-14465

2024

Volltextzugriff (PDF)

Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists

Bioorganic & medicinal chemistry letters, 2021-11, Vol.52, p.128384-128384, Article 128384

2021

Volltextzugriff (PDF)

BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration

Pulmonary pharmacology & therapeutics, 2019-06, Vol.56, p.56-62

2019

Volltextzugriff (PDF)

Structural Basis of the Negative Allosteric Modulation of 5-BDBD at Human P2X4 Receptors

Molecular pharmacology, 2022-01, Vol.101 (1), p.33-44

2022

Volltextzugriff (PDF)

P2X7-dependent, but differentially regulated release of IL-6, CCL2, and TNF-α in cultured mouse microglia

Glia, 2014-04, Vol.62 (4), p.592-607

2014

Volltextzugriff (PDF)

Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy

The Journal of neuroscience, 2016-06, Vol.36 (22), p.5920-5932

2016

Volltextzugriff (PDF)

Neuroprotective and neuro-rehabilitative effects of acute purinergic receptor P2X4 (P2X4R) blockade after ischemic stroke

Experimental neurology, 2020-07, Vol.329, p.113308-113308, Article 113308

2020

Volltextzugriff (PDF)

4‑Methyl-6,7-dihydro‑4H‑triazolo[4,5‑c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate

Journal of medicinal chemistry, 2017-06, Vol.60 (11), p.4559-4572

2017

Volltextzugriff (PDF)

Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP

Nature communications, 2016-02, Vol.7 (1), p.10555-10555, Article 10555

2016

Volltextzugriff (PDF)

Piperazine squaric acid diamides, a novel class of allosteric P2X7 receptor antagonists

European journal of medicinal chemistry, 2021-12, Vol.226, p.113838-113838, Article 113838

2021

Volltextzugriff (PDF)

Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia

Neuropsychopharmacology (New York, N.Y.), 2018-12, Vol.43 (13), p.2586-2596

2018

Volltextzugriff (PDF)

Mapping the Site of Action of Human P2X7 Receptor Antagonists AZ11645373, Brilliant Blue G, KN-62, Calmidazolium, and ZINC58368839 to the Intersubunit Allosteric Pocket

Molecular pharmacology, 2019-09, Vol.96 (3), p.355-363

2019

Volltextzugriff (PDF)

Characterization of the antagonist actions of 5-BDBD at the rat P2X4 receptor

Neuroscience letters, 2019-01, Vol.690, p.219-224

2019

Volltextzugriff (PDF)

Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ‐47965567

British journal of pharmacology, 2013-10, Vol.170 (3), p.624-640

2013

Volltextzugriff (PDF)

P2X receptors: Insights from the study of the domestic dog

Neuropharmacology, 2023-02, Vol.224, p.109358, Article 109358

2023

Volltextzugriff (PDF)

The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment

Oncogene, 2019-05, Vol.38 (19), p.3636-3650

2019

Volltextzugriff (PDF)

Is there a biochemical basis for purinergic P2X3 and P2X4 receptor antagonists to be considered as anti-seizure medications?

Biochemical pharmacology, 2024-04, Vol.222, p.116046, Article 116046

2024

Volltextzugriff (PDF)

Synthesis and Pharmacological Evaluation of Novel Non-nucleotide Purine Derivatives as P2X7 Antagonists for the Treatment of Neuroinflammation

Journal of medicinal chemistry, 2021-02, Vol.64 (4), p.2272-2290

2021

Volltextzugriff (PDF)

1 – 25 von 725

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(705)
Mit Volltextzugriff
(669)

Publikationsform

Artikel
(724)
Buchkapitel
(1)

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Animals
(600)
Science & Technology
(542)
Life Sciences & Biomedicine
(534)
Purinergic P2x Receptor Antagonists - Pharmacology
(368)
Humans
(308)
Male
(291)
Rats
(275)
Adenosine Triphosphate - Pharmacology
(263)
Pharmacology & Pharmacy
(237)
Adenosine Triphosphate - Analogs & Derivatives
(193)
Neurosciences
(186)
Receptors, Purinergic P2x7 - Metabolism
(180)
Purinergic P2 Receptor Antagonists
(176)
Neurosciences & Neurology
(174)
Mice
(173)
Atp
(158)
Biological And Medical Sciences
(122)
Dose-Response Relationship, Drug
(122)
Adenosine Triphosphate - Metabolism
(121)
Rats, Sprague-Dawley
(121)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Activation and regulation of purinergic P2X receptor channels

Action of MK‐7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation

X-ray structures define human P2X(3) receptor gating cycle and antagonist action

Purinergic P2X receptors: Structural models and analysis of ligand-target interaction

The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease

P2X7 receptor antagonism: Implications in diabetic retinopathy

P2X7 receptor in multifaceted cellular signalling and its relevance as a potential therapeutic target in different diseases

Discovery of Triazolopyrimidine Derivatives as Selective P2X3 Receptor Antagonists Binding to an Unprecedented Allosteric Site as Evidenced by Cryo-Electron Microscopy

Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists

BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration

Structural Basis of the Negative Allosteric Modulation of 5-BDBD at Human P2X4 Receptors

P2X7-dependent, but differentially regulated release of IL-6, CCL2, and TNF-α in cultured mouse microglia

Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy

Neuroprotective and neuro-rehabilitative effects of acute purinergic receptor P2X4 (P2X4R) blockade after ischemic stroke

4‑Methyl-6,7-dihydro‑4H‑triazolo[4,5‑c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate

Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP

Piperazine squaric acid diamides, a novel class of allosteric P2X7 receptor antagonists

Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia

Mapping the Site of Action of Human P2X7 Receptor Antagonists AZ11645373, Brilliant Blue G, KN-62, Calmidazolium, and ZINC58368839 to the Intersubunit Allosteric Pocket

Characterization of the antagonist actions of 5-BDBD at the rat P2X4 receptor

Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ‐47965567

P2X receptors: Insights from the study of the domestic dog

The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment

Is there a biochemical basis for purinergic P2X3 and P2X4 receptor antagonists to be considered as anti-seizure medications?

Synthesis and Pharmacological Evaluation of Novel Non-nucleotide Purine Derivatives as P2X7 Antagonists for the Treatment of Neuroinflammation

Aktive Filter

Suchergebnisse filtern